Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c
August 14, 2024 4:20 PM EDTArcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($0.42), $0.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $29.09 million.
For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.
... More